The relationship between adipokines, metabolic parameters and insulin resistance in patients with metabolic syndrome and type 2 diabetes

Journal of International Medical Research

Volumn 37, Issue 6, 2009, Pages 1803-1812

  Lee, J M ^a   Kim, S R ^a   Yoo, S J ^a   Hong, O K ^a   Son, H S ^a   Chang, Sang Ah ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Adipokines; Insulin resistance; Metabolic syndrome; Type 2 diabetes

Indexed keywords

ADIPOCYTOKINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 74949113508     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700616     Document Type: Article

References (35)

1. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final report. Circulation 2002; 106: 3143-3421.
2. Alberti KG, Zimmet P, Shaw J: Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480.
3. Ahima RS, Flier JS: Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11: 327-332.
4. Bays H, Mandarino L, DeFronzo R: Role of the adipocyte, free fatty acids, and ectopic fat in the pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89: 463-478.
5. Yang X, Jansson P-A, Nagaev I, et al: Evidence of impaired adipogenesis in insulin resistance. Biochem Biophys Res Commun 2004; 317: 1045-1051.
6. Yaspelkis BB, Ansari L, Ramey EL, et al: Chronic leptin administration increased insulinstimulated skeletal muscle glucose uptake and transport. Metabolism 1999; 48: 671-676.
7. Shimomura I, Hammer RE, Ikemoto S, et al: Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401: 73-76.
8. Maffei M, Halaas J, Ravussin E, et al: Leptin levels in human and rodent: measurement of plasma leptin and obRNA in obese and weightreduced subjects. Nat Med 1995; 1: 1155-1161.
9. Whitehead JP, Richards AA, Hickman IJ, et al: Adiponectin - a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8: 264-280.
10. Yang WS, Lee WJ, Funahashi T, et al: Plasma adiponectin levels in overweight and obese Asians. Obes Res 2002; 10: 1104-1110.
11. Ryo M, Nakamura T, Kihara S, et al: Adiponectin as a biomarker of the metabolic syndrome. Circ J 2002; 68: 975-981.
12. Hulver MW, Zheng D, Tanner CJ, et al: Adiponectin is not altered with exercise training despite enhanced insulin action. Am J Physiol Endocrinol Metab 2002; 283: E861-E865.
13. Abbasi F, Lamendola C, McLaughlin T, et al: Plasma adiponectin concentrations do not increase in association with moderate weight loss in insulin-resistant obese women. Metabolism 2004; 53: 280-283.
14. Satoh N, Naruse M, Usui T, et al: Leptin to adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients. Diabetes Care 2004; 27: 2488-2490.
15. Inoe M, Yano M, Yamakado M, et al: Relationship between the adiponectin - leptin ratio and parameters of insulin resistance in subjects without hyperglycemia. Metabolism 2006; 55: 1248-1254.
16. Pajvani UB, Hawkins M, Combs TP, et al: Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedionemediated improvement in insulin sensitivity. J Biol Chem 2004; 279: 12152-12162.
17. Katsuki A, Suematsu M, Gabazza EC, et al: Decreased high molecular weight adiponectin to total adiponectin ratio in sera is associated with insulin resistance in Japanese metabolically obese, normal-weight men with normal glucose tolerance. Diabetes Care 2006; 29: 2327-2328.
18. Lara-Castro C, Luo N, Wallace P, et al: Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 2006; 55: 249-259.
19. Xydakis AM, Case CC, Jones PH, et al: Adiponectin, inflammation, and the expression of metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab 2004; 89: 2697-2703.
20. Bermudez EA, Rifai N, Buring J, et al: Interrelationships among circulating IL-6, Creactive protein and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002; 22: 1668-1673.
21. Weyer C, Funahashi T, Tanaka S, et al: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
22. Arita Y, Kihara S, Ouchi N, et al: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
23. Fisher FF, Trujillo ME, Hanif W, et al: Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia 2005; 48: 1084-1087.
24. Hara K, Horikoshi M, Yamauchi T, et al: Measurement of the high molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006; 29: 1357-1362.
25. Mohamed-Ali V, Goodrick S, Rawesh A, et al: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200.
26. Considine RV, Sinha MK, Heiman ML, et al: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295.
27. Vidal H, Auboeuf D, De Vos P, et al: The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue. J Clin Invest 1996; 98: 251-255.
28. Marfella R, Esposito K, Siniscalchi M, et al: Effect of weight loss on cardiac synchronization and proinflammatory cytokines in premenopausal obese women. Diabetes Care 2004; 27: 47-52.
29. Winkler G, Kiss S, Keszthelyi L, et al: Expression of tumor necrosis factor (TNF)-α protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-α, soluble serum TNF receptor-2 concentration and C-peptide level. Eur J Endocrinol 2003; 149: 129-135.
30. Bastard J, Jardel C, Bruckert E, et al: Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000; 85: 3338-3342.
31. Koistinen HA, Bastard JP, Dusserre E, et al: Subcutaneous adipose tissue expression of tumour necrosis factor-α is not associated with whole body insulin resistance in obese nondiabetic or in type 2 diabetic subjects. Eur J Clin Invest 2000; 30: 302-310.
32. Mojiminiyi OA, Abdella NA, Arouj M, et al: Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with type 2 diabetes. Int J Obese (Lond) 2007; 31: 213-220.
33. Salmenniemi U, Ruotsalainen E, Pihlajamaki J, et al: Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines and adhesion molecules in subjects with metabolic syndrome. Circulation 2004; 110: 3842-3848.
34. Choi KM, Lee J, Lee KW, et al: Comparison of serum concentrations of C-reactive protein, TNF-α, and IL-6 between elderly Korean women with normal and impaired glucose tolerance. Diabetes Res Clin Pract 2004; 64: 99-106.
35. Haffner SM, Greenberg AS, Weston WM, et al: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.